Creo Medical Group plc

("Creo" the "Company" or the "Group")

Presentation at Growth and Innovation Forum 2022

Patient testimonials following SSD procedures to feature in management's presentation

Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces that it will be presenting at the virtual Growth and Innovation Forum 2022 on Tuesday 8 February, to be hosted by Cenkos in partnership with Proactive, and sponsored by PrimaryBid. 

This is a one-day investor event exhibiting companies focused on growth and technology, attracting both institutional and retail investors. Creo's management team will be presenting at 13:00 GMT. To register for the afternoon session, click here. The slides will be made available on the Company website shortly after the event.

For further information on the event, please visit the website here.

No new material information will be disclosed at the event, but will include testimonials from patients who have recently undergone procedures using Creo's flagship Speedboat® Inject device.

Commenting on the recent removal of a 10cm lesion via a Speedboat Submucosal Dissection (SSD), the patient  described the after-effects of the SSD procedure as being "negligible, manageable to the extent to it being a non-event.

"I still couldn't square how much work was done for how little I felt that work had been done…I just feel that I'm back to normal, completely."

About Reach announcements

Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.

Enquiries:

About Creo Medical 

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions.  CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option for procedures.

For more information, please refer to the website www.creomedical.com